Canton Fitzgerald's Elemer Piros initiated Dimension Therapeutics Inc DMTX at Buy with a $32.00 price objective.
"Dimension has assembled a suite of potentially best-in-class liver-targeted gene therapies" with a $275-million-dollar licensing agreement with Bayer Healthcare, said Piros. The analyst was impressed with Dimension's intellectual property and "world-class pharma and biotech executives" which would allow Dimension to "accomplish an ambitious set of development goals."
Additionally, Piros noted that Ornithine transcarbamylase (OTC) deficiency, an issue which Dimension wishes to solve, is currently being treated with a drug that costs ~$250,000 a year taken for a lifetime."
Shares of Dimension Therapeutics last closed at $8.45.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
